5 hours ago
HomeMarket NewsStocks NewsSenores Pharmaceuticals to acquire Apnar Pharma for enterprise value of ₹91 crore
The acquisition has been valued at an enterprise value of about ₹91 crore. Of this, around ₹76 crore comprises total debt and expected liabilities related to the manufacturing plant that will be taken over by Senores Pharmaceuticals, while the remaining about ₹15 crore will be paid in cash. Shares of Senores Pharmaceuticals Ltd ended at ₹817.00, up by ₹30.90, or 3.93%, on the BSE.
2 Min Read
Gujarat-based Senores Pharmaceuticals Ltd on Monday (December 15) said it has entered into a share purchase agreement to acquire 100% equity stake in Apnar Pharma Private Ltd in two tranches, following approval from the management committee of its board. Upon completion of the transaction, Apnar Pharma will become a wholly owned subsidiary of Senores Pharmaceuticals.
The acquisition has been valued at an enterprise value of about ₹91 crore. Of this, around ₹76 crore comprises total debt and expected liabilities related to the manufacturing plant that will be taken over by Senores Pharmaceuticals, while the remaining about ₹15 crore will be paid in cash. The cash component will be paid in two tranches, with 75% to be paid in the first tranche and the balance 25% in the second tranche.
The transaction is expected to be completed in two stages. The first tranche is targeted for completion within the current financial year by March 2026, while the second tranche is expected to be completed by the second quarter of FY27.
Also Read: Senores Pharma secures Philippine FDA nod for 10 products
Apnar Pharma Private Ltd is a pharmaceutical company engaged in the manufacture of generic pharmaceutical formulations. It operates a manufacturing facility near Vadodara, Gujarat, which has approvals from the US Food and Drug Administration, UK-MHRA and Health Canada. The company was incorporated in Gujarat on December 12, 2014.
The turnover of Apnar Pharma stood at ₹15.75 crore in March 2023, ₹27.56 crore in March 2024 and ₹14.21 crore in March 2025. The company has its presence in India. Senores Pharmaceuticals stated that the acquisition does not fall under related party transactions, and that neither the promoter nor promoter group entities have any interest in Apnar Pharma.
Shares of Senores Pharmaceuticals Ltd ended at ₹817.00, up by ₹30.90, or 3.93%, on the BSE.
Also Read: Senores Pharma shares surge to post-listing high after 15% jump on Q1 results
